177Lu-BetaBart

1 clinical trials involving this therapy/drug

This is not medical advice - consult your oncologist

Descriptions are automatically translated with AI assistance. Always verify details in the original on ClinicalTrials.gov and consult your treating physician.

RecruitingPhase I/IIBreast cancerLung cancerOvarian cancerCervical cancerColorectal cancerProstate cancerHead and neck cancerOther cancersTriple negative (TNBC)Metastatic / advanced

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

NCT07189871ClinicalTrials.gov ↗

A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Full details →

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.